M. Ruda

Protection of ischemic myocardium by exogenous phosphocreatine (neoton): pharmacokinetics of phosphocreatine, reduction of infarct size, stabilization of sarcolemma of ischemic cardiomyocytes, and antithrombotic action.

V. Saks, Victor G. Sharov, I. I. Shepeleva, 1986, Biochemical medicine and metabolic biology.

Modulating effect of ischemia on late potentials

I. Savelieva, J. A. Gomes, I. Strazhesko, 1993 .

Effect of nitroglycerin on size of an experimental myocardial infarct

N. V. Kaverina, N. Afonskaya, M. Ruda, 1981, Bulletin of Experimental Biology and Medicine.

Fibrinogen‐immobilized Urokinase Demonstrates Increased Thrombolytic Activity in Animal Experiments

V. Torchilin, A. Maksimenko, E. Tischenko, 1990, Annals of the New York Academy of Sciences.

Diagnostic Value of Immune Cholesterol as a Marker for Atherosclerosis

V. Tertov, A. Orekhov, A. Deev, 1995, Journal of cardiovascular risk.

Antiatherosclerotic effects of anipamil, verapamil and other calcium antagonists studied on cell culture

V. Tertov, A. Orekhov, A. Lyakishev, 1990 .

Atherosclerosis-related effects of verapamil, anipamil and other calcium antagonists studied on cell culture

V. Tertov, A. Orekhov, A. Lyakishev, 1990 .